Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac
Junco, Jesús A, Rodríguez, Ranfis, Fuentes, Franklin, Baladrón, Idania, Castro, Maria D, Calzada, Lesvia, Valenzuela, Carmen, Bover, Eddy, Pimentel, Eulogio, Basulto, Roberto, Arteaga, Niurka, Cid-Arregui, Angel, Sariol, Francisco, González, Lourdes, Porres-Fong, Liliana, Medina, María, Rodríguez, Ayni, Garay, A Hilda, Reyes, Osvaldo, López, Matilde, de Quesada, Lourdes, Alvarez, Allelin, Martínez, Carolina, Marrero, Marleny, Molero, Guillermo, Guerra, Alfredo, Rosales, Pedro, Capote, Carlos, Acosta, Sahily, Vela, Idania, Arzuaga, Lina, Campal, Ana, Ruiz, Erlán, Rubio, Elier, Cedeño, Pável, Sánchez, María Carmen, Cardoso, Pedro, Morán, Rolando, Fernández, Yairis, Campos, Magalys, Touduri, Henio, Bacardi, Dania, Feria, Indalecio, Ramirez, Amilcar, Cosme, Karelia, Saura, Pedro López, Quintana, Maricel, Muzio, Verena, Bringas, Ricardo, Ayala, Marta, Mendoza, Mario, Fernández, Luis E, Carr, Adriana, Herrera, Luis, Guillén, Gerardo
Published in Frontiers in oncology (2019)
Published in Frontiers in oncology (2019)
Get full text
Journal Article